Epigenica commercializes the proprietary EpiFinder platform for simultaneous analysis of multiple epigenetic markers across large sample sets. Its flagship product, EpiFinder Genome, is already available, and the company plans upcoming launches of EpiFinder Global and EpiFinder cNUC kits. The platform is positioned for drug discovery and drug development applications and aims to make epigenetic biomarker analysis faster, scalable, and more affordable. The company will also expand its service offering and build out data infrastructure to support customers. Management says the funding will accelerate product development, commercialization, and entry into the US market. The company is led by CEO Mohamad Takwa and is based in Stockholm.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2025